Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. ANET
3. NKE
4. BE
5. PANW
6. CL
7. SNDK
8. TAP
9. DELL
10. ROIV

Go back to Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 34.87 --0 (-0%)
Previous Close $34.87    52 Week High $5.17 
Open $34.87    52 Week Low $0.94 
Day High $34.87    P/E N/A 
Day Low $34.87    EPS $0.00 
Volume 5,069